Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors

• Published in: Cancer communications (London, England) England), 2023-02, Vol.43 (2), p.280-284
• Main Authors: Chen, Zhiwei, Zhu, Peng, Liu, Zuojin, Zhu, Bin, Yin, Guobing, Ming, Jia, Song, Rui, Pan, Qingbo, Li, Tong, Jiang, Xingwei, Wang, Bing, Liu, Shuaibin, Cai, Hongxing, Wang, Jingjie, Han, Yuling, Lin, Zijing, Hong, Yang, Chen, Min, Peng, Mingli, Hu, Lina, Cai, Dachuan, Ren, Hong
• Format: Article
• Language: English
• Subjects: Antibodies; Cancer therapies; Chemotherapy; Coronaviruses; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - therapeutic use; Humans; Immunity, Humoral; Immunotherapy; Letter to the Editor; Neoplasms; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Tumors
• ISSN: 2523-3548; 2523-3548
• DOI: 10.1002/cac2.12368

[...]there is an urgent need to investigate the safety and humoral immune responses of inactivated vaccines in cancer patients. [...]although the overall frequency of RBD+ MBCs was higher in cancer patients, immune memory was impaired. [...]an assessment of the third “booster” dose and immunity against variants of concerns was not performed, which hindered further analysis, such as the immunity against Delta or Omicrons variants after inactivated vaccination. [...]only patients with solid tumors were included in our study, while patients with hematologic malignancies were excluded, which might have impacted the results, given the higher immunosuppressive status of the latter [ 10].